JP2021525059A5 - - Google Patents

Info

Publication number
JP2021525059A5
JP2021525059A5 JP2020558493A JP2020558493A JP2021525059A5 JP 2021525059 A5 JP2021525059 A5 JP 2021525059A5 JP 2020558493 A JP2020558493 A JP 2020558493A JP 2020558493 A JP2020558493 A JP 2020558493A JP 2021525059 A5 JP2021525059 A5 JP 2021525059A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
seq
isolated antibody
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020558493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525059A (ja
JP7431750B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000503 external-priority patent/WO2019211665A1/en
Publication of JP2021525059A publication Critical patent/JP2021525059A/ja
Publication of JP2021525059A5 publication Critical patent/JP2021525059A5/ja
Priority to JP2024014317A priority Critical patent/JP7798931B2/ja
Application granted granted Critical
Publication of JP7431750B2 publication Critical patent/JP7431750B2/ja
Priority to JP2025281032A priority patent/JP2026076162A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020558493A 2018-04-30 2019-04-29 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用 Active JP7431750B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024014317A JP7798931B2 (ja) 2018-04-30 2024-02-01 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用
JP2025281032A JP2026076162A (ja) 2018-04-30 2025-12-24 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862664882P 2018-04-30 2018-04-30
US62/664,882 2018-04-30
PCT/IB2019/000503 WO2019211665A1 (en) 2018-04-30 2019-04-29 Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024014317A Division JP7798931B2 (ja) 2018-04-30 2024-02-01 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2021525059A JP2021525059A (ja) 2021-09-24
JP2021525059A5 true JP2021525059A5 (cg-RX-API-DMAC7.html) 2022-05-11
JP7431750B2 JP7431750B2 (ja) 2024-02-15

Family

ID=67396963

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020558493A Active JP7431750B2 (ja) 2018-04-30 2019-04-29 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用
JP2024014317A Active JP7798931B2 (ja) 2018-04-30 2024-02-01 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用
JP2025281032A Pending JP2026076162A (ja) 2018-04-30 2025-12-24 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024014317A Active JP7798931B2 (ja) 2018-04-30 2024-02-01 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用
JP2025281032A Pending JP2026076162A (ja) 2018-04-30 2025-12-24 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用

Country Status (21)

Country Link
US (3) US12202901B2 (cg-RX-API-DMAC7.html)
EP (1) EP3787746A1 (cg-RX-API-DMAC7.html)
JP (3) JP7431750B2 (cg-RX-API-DMAC7.html)
KR (1) KR102992188B1 (cg-RX-API-DMAC7.html)
CN (1) CN112218684A (cg-RX-API-DMAC7.html)
AR (1) AR114436A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019264029B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020022035A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098416A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002793A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020014681A2 (cg-RX-API-DMAC7.html)
EA (1) EA202092593A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20076576A (cg-RX-API-DMAC7.html)
IL (1) IL278276B2 (cg-RX-API-DMAC7.html)
MA (1) MA52504A (cg-RX-API-DMAC7.html)
MX (1) MX2020011498A (cg-RX-API-DMAC7.html)
PE (1) PE20210419A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551805A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202010388SA (cg-RX-API-DMAC7.html)
TW (1) TWI882957B (cg-RX-API-DMAC7.html)
WO (1) WO2019211665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7431750B2 (ja) 2018-04-30 2024-02-15 武田薬品工業株式会社 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用
AU2023249518A1 (en) * 2022-04-04 2024-10-17 Bird Rock Bio Sub, Inc. Prediction and treatment of fast progressing renal disease
EP4534672A1 (en) 2022-06-03 2025-04-09 Shionogi & Co., Ltd Antibody that binds to cannabinoid type 1 receptors
EP4539845A1 (en) * 2022-06-17 2025-04-23 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Peripheralization of centrally-acting cannabinoid-1 receptor antagonists by nanoparticles for the treatment metabolic related conditions
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途
WO2025257151A1 (en) * 2024-06-10 2025-12-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating ciliopathies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
WO2005023232A2 (en) 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
CA2915386A1 (en) * 2013-06-26 2014-12-31 Amgen Inc. Cb1 receptor antigen-binding proteins and uses thereof
KR102731863B1 (ko) 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
US10277406B1 (en) * 2014-09-05 2019-04-30 Digicert, Inc. Authentication process for issuing sequence of short-lived digital certificates
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
CA3000167A1 (en) * 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
JP7431750B2 (ja) 2018-04-30 2024-02-15 武田薬品工業株式会社 カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用

Similar Documents

Publication Publication Date Title
JP7781859B2 (ja) 抗ror1抗体及び関連の二重特異性結合タンパク質
JP2023134618A5 (cg-RX-API-DMAC7.html)
JP2019530434A5 (cg-RX-API-DMAC7.html)
JP2014509861A5 (cg-RX-API-DMAC7.html)
CN115698079A (zh) 抗cd79b抗体药物偶联物、其制备方法及其医药用途
JP2021520825A5 (cg-RX-API-DMAC7.html)
JP2021530960A5 (cg-RX-API-DMAC7.html)
JP2021534797A5 (cg-RX-API-DMAC7.html)
JP2017526370A5 (cg-RX-API-DMAC7.html)
JP2022524588A5 (cg-RX-API-DMAC7.html)
JP2010534478A5 (cg-RX-API-DMAC7.html)
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP2016503067A5 (cg-RX-API-DMAC7.html)
JP2022545741A5 (cg-RX-API-DMAC7.html)
JP2009523154A5 (cg-RX-API-DMAC7.html)
JP2010517513A5 (cg-RX-API-DMAC7.html)
JP2016505546A5 (cg-RX-API-DMAC7.html)
JP2024535712A5 (cg-RX-API-DMAC7.html)
AU2014248636B2 (en) Humanized anti-N2 antibodies
WO2019195313A1 (en) Anti-vegf antagonist and pedf agonist constructs and uses thereof
JP2018522540A5 (cg-RX-API-DMAC7.html)
JP2023519962A5 (cg-RX-API-DMAC7.html)
CA2944049A1 (en) Antibodies that bind human cannabinoid 1 (cb1) receptor
CA3096791C (en) Cell engaging binding molecules
JP2013521252A5 (cg-RX-API-DMAC7.html)